CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo

Leukemia. 2015 Jun;29(6):1437-41. doi: 10.1038/leu.2015.10. Epub 2014 Jan 12.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects*
  • Bridged Bicyclo Compounds, Heterocyclic / pharmacology*
  • Cells, Cultured
  • Cyclin-Dependent Kinase 9 / antagonists & inhibitors*
  • Cyclin-Dependent Kinase 9 / metabolism
  • Fibroblasts / cytology
  • Fibroblasts / drug effects
  • Fibroblasts / metabolism
  • Humans
  • Lymphoma, B-Cell / metabolism
  • Lymphoma, B-Cell / pathology*
  • Mice
  • Mice, Inbred C57BL
  • Myeloid Cell Leukemia Sequence 1 Protein / antagonists & inhibitors*
  • Myeloid Cell Leukemia Sequence 1 Protein / metabolism
  • Proto-Oncogene Proteins c-myc / metabolism*
  • Pyridinium Compounds / pharmacology*

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • MCL1 protein, human
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Proto-Oncogene Proteins c-myc
  • Pyridinium Compounds
  • dinaciclib
  • Cyclin-Dependent Kinase 9